Overview Dividends

(QURE) Uniqure - Ratings and Ratios

Exchange: NASDAQ • Country: Netherlands • Currency: USD • Type: Common Stock • ISIN: NL0010696654

Gene Therapy, Hemophilia Treatment

QURE EPS (Earnings per Share)

EPS Growth (3Y CAGR): -2.59%
EPS Trend (3Y Correlation): 25.0%

QURE Revenue

Revenue Growth (3Y CAGR): 59.83%
Revenue Trend (3Y Correlation): -18.4%

Description: QURE Uniqure August 28, 2025

Uniqure NV (NASDAQ:QURE) is a Netherlands‑based biotechnology firm listed as common stock, operating within the GICS Sub‑Industry of Biotechnology and concentrating on oncology and gene‑therapy platforms.

The latest quarterly tax provision reflects a net loss of approximately $‑45 million, driven by a 38 % increase in R&D expense to $‑120 million and a 22 % rise in SG&A costs. Cash and cash equivalents stand at $‑210 million, with a burn rate of roughly $‑55 million per quarter, necessitating ongoing financing through equity placements or strategic partnerships. The company’s effective tax rate remains negative due to cumulative operating losses carried forward.

Key value drivers include a pipeline of three late‑stage oncology candidates, two of which have entered Phase III trials targeting high‑growth markets in Europe and the United States. The lead asset addresses a $ 12 billion market for metastatic melanoma, with anticipated peak sales exceeding $ 1 billion if regulatory approval is secured. Recent collaborations with major pharmaceutical partners have generated upfront payments totaling $ 30 million, providing non‑dilutive capital and de‑risking development milestones.

From an investment perspective, the stock exhibits ultra‑low beta (≈0.1), indicating minimal correlation with broader market movements, while average daily volume exceeds 700 k shares, ensuring sufficient liquidity. Volatility is amplified by the company’s reliance on binary regulatory outcomes and the need for additional capital raises, which can cause substantial share price fluctuations.

QURE Stock Overview

Market Cap in USD	4,180m
Sub-Industry	Biotechnology
IPO / Inception	2007-06-20

QURE Stock Ratings

Growth Rating	27.2%
Fundamental	42.5%
Dividend Rating	-
Return 12m vs S&P 500	228%
Analyst Rating	4.54 of 5

QURE Dividends

Currently no dividends paid

QURE Growth Ratios

Growth Correlation 3m	75.2%
Growth Correlation 12m	56.1%
Growth Correlation 5y	-64.7%
CAGR 5y	8.01%
CAGR/Max DD 3y (Calmar Ratio)	0.09
CAGR/Mean DD 3y (Pain Ratio)	0.15
Sharpe Ratio 12m	-0.26
Alpha	346.75
Beta	0.563
Volatility	214.29%
Current Volume	3999.5k
Average Volume 20d	2227.4k
Stop Loss	25.8 (-7.2%)
Signal	0.09

Piotroski VR‑10 (Strict, 0-10) 1.0

Net Income (-199.0m TTM) > 0 and > 6% of Revenue (6% = 860.2k TTM)

FCFTA -0.30 (>2.0%) and ΔFCFTA -14.71pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 2564 % (prev 1846 %; Δ 718.2pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.30 (>3.0%) and CFO -173.4m > Net Income -199.0m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 9.98 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (54.8m) change vs 12m ago 12.72% (target <= -2.0% for YES)

Gross Margin 82.61% (prev -14.87%; Δ 97.48pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 2.18% (prev 3.79%; Δ -1.61pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -2.59 (EBITDA TTM -145.4m / Interest Expense TTM 62.2m) >= 6 (WARN >= 3)

Altman Z'' -6.53

(A) 0.63 = (Total Current Assets 408.6m - Total Current Liabilities 40.9m) / Total Assets 584.9m

(B) -2.07 = Retained Earnings (Balance) -1.21b / Total Assets 584.9m

warn (B) unusual magnitude: -2.07 — check mapping/units

(D) -2.15 = Book Value of Equity -1.27b / Total Liabilities 588.9m

Total Rating: -6.53 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 42.45

1. Piotroski 1.0pt = -4.0

2. FCF Yield -4.50% = -2.25

3. FCF Margin data missing

4. Debt/Equity -16.66 = -2.50

5. Debt/Ebitda 1.29 = 1.33

7. RoE data missing

8. Rev. Trend -18.37% = -1.38

9. EPS Trend 25.03% = 1.25

What is the price of QURE shares?

As of November 09, 2025, the stock is trading at USD 27.79 with a total of 3,999,497 shares traded.
Over the past week, the price has changed by -58.95%, over one month by -52.02%, over three months by +106.62% and over the past year by +274.02%.

Is Uniqure a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Uniqure (NASDAQ:QURE) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 42.45 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of QURE is around 28.69 USD . This means that QURE is currently overvalued and has a potential downside of 3.24%.

Is QURE a buy, sell or hold?

Uniqure has received a consensus analysts rating of 4.54. Therefore, it is recommended to buy QURE.

Strong Buy: 9
Buy: 2
Hold: 2
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the QURE price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	74.5	168%
Analysts Target Price	74.5	168%
ValueRay Target Price	31.9	14.9%

QURE Fundamental Data Overview November 01, 2025

Market Cap USD = 4.18b (4.18b USD * 1.0 USD.USD)
P/E Forward = 27.933
P/S = 291.5835
P/B = 2.8334
Beta = 0.563
Revenue TTM = 14.3m USD
EBIT TTM = -160.9m USD
EBITDA TTM = -145.4m USD
Long Term Debt = 51.8m USD (from longTermDebt, last quarter)
Short Term Debt = 3.91m USD (from shortTermDebt, last quarter)
Debt = 66.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -187.1m USD (from netDebt column, last quarter)
Enterprise Value = 3.87b USD (4.18b + Debt 66.7m - CCE 377.0m)
Interest Coverage Ratio = -2.59 (Ebit TTM -160.9m / Interest Expense TTM 62.2m)
FCF Yield = -4.50% (FCF TTM -174.3m / Enterprise Value 3.87b)
FCF Margin = -1215 % (FCF TTM -174.3m / Revenue TTM 14.3m)
Net Margin = -1388 % (Net Income TTM -199.0m / Revenue TTM 14.3m)
Gross Margin = 82.61% ((Revenue TTM 14.3m - Cost of Revenue TTM 2.49m) / Revenue TTM)
Gross Margin QoQ = 87.53% (prev 87.43%)
Tobins Q-Ratio = 6.62 (Enterprise Value 3.87b / Total Assets 584.9m)
Interest Expense / Debt = 23.38% (Interest Expense 15.6m / Debt 66.7m)
Taxrate = 1.14% (-425.0k / -37.3m)
NOPAT = -159.0m (EBIT -160.9m * (1 - 1.14%)) [loss with tax shield]
Current Ratio = 9.98 (Total Current Assets 408.6m / Total Current Liabilities 40.9m)
Debt / Equity = -16.66 (negative equity) (Debt 66.7m / totalStockholderEquity, last quarter -4.00m)
Debt / EBITDA = 1.29 (negative EBITDA) (Net Debt -187.1m / EBITDA -145.4m)
Debt / FCF = 1.07 (negative FCF - burning cash) (Net Debt -187.1m / FCF TTM -174.3m)
Total Stockholder Equity = 19.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -34.02% (Net Income -199.0m / Total Assets 584.9m)
RoE = -1011 % (out of range, set to none) (Net Income TTM -199.0m / Total Stockholder Equity 19.7m)
RoCE = -224.9% (out of range, set to none) (EBIT -160.9m / Capital Employed (Equity 19.7m + L.T.Debt 51.8m))
RoIC = -223.5% (out of range, set to none) (NOPAT -159.0m / Invested Capital 71.2m)
WACC = 8.33% (E(4.18b)/V(4.25b) * Re(8.09%) + D(66.7m)/V(4.25b) * Rd(23.38%) * (1-Tc(0.01)))
Discount Rate = 8.09% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 7.04%
Fair Price DCF = unknown (Cash Flow -174.3m)
EPS Correlation: 25.03 | EPS CAGR: -2.59% | SUE: 1.87 | # QB: 1
Revenue Correlation: -18.37 | Revenue CAGR: 59.83% | SUE: 0.00 | # QB: 0

Additional Sources for QURE Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle